Clinical Trials - May 27, 2022
Gedea Biotech to Start EpHect Clinical Trial
Gedea Biotech has received regulatory approval from the Ethics Committee and the Swedish Medical Products Agency and will start the EpHect clinical study of its lead product, pHyph, a vaginal tablet for topical treatment. The open-labelled study is designed to confirm the safety and efficacy of pHyph in treating adult women with confirmed Vulvo Vaginal […]
Business Award - May 2, 2022
Gedea named Rapidus Company of the Year
Gedea Biotech has been named Rapidus Company of the Year by a jury along with the Rapidus news agency, which monitors the strong growth industries in Skåne County and the Copenhagen area. The company ranked highest in strong competition with all of Skåne’s future hopefuls in fields ranging from technology to pharmaceuticals. Many highly successful […]
Clinical Trials - February 8, 2022
Gedea completes recruitment for NEFERTITI trial
Gedea Biotech has successfully completed recruitment of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The randomized double-blind placebo-controlled study is designed to confirm the safety and efficacy of pHyph and is coordinated by Nottingham University NHS Hospitals Trust across 6 UK […]
Collaboration - December 22, 2021
Gedea receives funding for microbiome research project
Gedea Biotech has received funding for a research project with the Centre for Translational Microbiome Research at Karolinska Institutet (KI), for its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The project goal is to better understand the microbial etiology of bacterial vaginosis (BV) and factors associated with successful, antibiotic-free […]
In a new job - December 1, 2021
Gedea Biotech appoints new Chair
Ton Berkien has been elected Chairman of the Board of Directors of Gedea Biotech. He replaces Olov Sterner, one of the founders of Gedea who continues as a board member. The appointment further strengthens the Board of Directors business development expertise, with Berkien bringing 20 years of experience in business development, and M&A, states Gedea. […]
Intellectual Property - October 27, 2021
Gedea Biotech granted European patent
The company has been granted a patent from the European Patent Office, covering the treatment of fungal infections with compound glucono-δ-lactone (GDL). The patent is valid in 36 European countries and can be kept in force until the 6th of April 2037. Gedea Biotech has previously announced that the corresponding patent is approved in the […]
